National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain, which enhances ...

The introduction of Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, has transformed management, though resistance mutations (BTK C481S) necessitate molecular monitoring. Low- and High ...